share_log

STAAR Surgical (NASDAQ:STAA) Shares Sold by Metropolitan Life Insurance Co NY

STAAR Surgical (NASDAQ:STAA) Shares Sold by Metropolitan Life Insurance Co NY

纽约大都会人寿保险公司出售的星空外科(纳斯达克代码:STAA)股票
Defense World ·  2022/09/08 05:41

Metropolitan Life Insurance Co NY decreased its holdings in shares of STAAR Surgical (NASDAQ:STAA – Get Rating) by 85.1% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 2,994 shares of the medical instruments supplier's stock after selling 17,033 shares during the period. Metropolitan Life Insurance Co NY's holdings in STAAR Surgical were worth $239,000 at the end of the most recent quarter.

根据纽约大都会人寿保险公司向美国证券交易委员会披露的最新信息,该公司在第一季度减持了星空外科(STAAR Surgical)股票(纳斯达克代码:STAA-GET评级)85.1%。该基金在此期间出售了17,033股后,持有这家医疗器械供应商的2,994股股票。截至最近一个季度末,纽约大都会人寿保险公司持有的STAAR Surgical股份价值23.9万美元。

Several other hedge funds have also recently modified their holdings of STAA. Rise Advisors LLC purchased a new position in shares of STAAR Surgical in the fourth quarter worth $25,000. Covestor Ltd acquired a new position in shares of STAAR Surgical in the fourth quarter valued at about $39,000. Point72 Hong Kong Ltd acquired a new stake in shares of STAAR Surgical during the fourth quarter worth about $100,000. PNC Financial Services Group Inc. increased its holdings in STAAR Surgical by 18.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,287 shares of the medical instruments supplier's stock worth $102,000 after buying an additional 202 shares during the period. Finally, Meeder Asset Management Inc. lifted its stake in STAAR Surgical by 815.0% during the 1st quarter. Meeder Asset Management Inc. now owns 1,345 shares of the medical instruments supplier's stock valued at $107,000 after acquiring an additional 1,198 shares during the period. Institutional investors and hedge funds own 96.38% of the company's stock.

其他几家对冲基金最近也调整了对STAA的持股。Rise Advisors LLC在第四季度购买了STAAR Surgical的新头寸,价值25,000美元。Covestor Ltd在第四季度收购了STAAR Surgical股票的新头寸,价值约3.9万美元。Point72 Hong Kong Ltd在第四季度收购了STAAR Surgical价值约10万美元的新股。PNC金融服务集团在第一季度增持了STAAR Surgical 18.6%的股份。PNC金融服务集团现在持有这家医疗器械供应商的1,287股股票,价值102,000美元,在此期间又购买了202股。最后,弥德资产管理公司在第一季度增持了星空外科815.0%的股份。Meeder Asset Management Inc.在此期间增持了1,198股Meeder Asset Management Inc.,目前持有这家医疗器械供应商1,345股股票,价值10.7万美元。机构投资者和对冲基金持有该公司96.38%的股票。

Get
到达
STAAR Surgical
STAAR外科
alerts:
警报:

STAAR Surgical Price Performance

STAAR手术性价比

STAA stock opened at $94.33 on Thursday. STAAR Surgical has a 1 year low of $49.03 and a 1 year high of $162.69. The firm has a market capitalization of $4.53 billion, a PE ratio of 140.79 and a beta of 1.04. The business has a 50 day simple moving average of $86.12 and a 200-day simple moving average of $73.75.

周四,Staa的股票开盘报94.33美元。STAAR Surgical的一年低点为49.03美元,一年高位为162.69美元。该公司市值为45.3亿美元,市盈率为140.79,贝塔系数为1.04.该业务的50日简单移动均线切入位在86.12美元,200日简单移动均线切入位在73.75美元。

STAAR Surgical (NASDAQ:STAA – Get Rating) last issued its earnings results on Wednesday, August 10th. The medical instruments supplier reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.24 by $0.02. STAAR Surgical had a return on equity of 13.99% and a net margin of 12.84%. The business had revenue of $81.10 million during the quarter, compared to the consensus estimate of $80.12 million. During the same period last year, the company earned $0.19 EPS. The company's revenue for the quarter was up 30.0% on a year-over-year basis. On average, equities research analysts expect that STAAR Surgical will post 0.68 EPS for the current year.
星空外科(纳斯达克代码:STAA-GET Rating)最近一次发布财报是在8月10日星期三。这家医疗器械供应商公布本季度每股收益(EPS)为0.26美元,超出分析师普遍预期的0.24美元,超出0.02美元。STAAR Surgical的股本回报率为13.99%,净利润率为12.84%。该业务本季度的收入为8110万美元,而普遍预期为8012万美元。去年同期,该公司每股收益为0.19美元。该公司当季营收较上年同期增长30.0%。股票研究分析师平均预计,STAAR Surgical本年度每股收益将为0.68美元。

Wall Street Analyst Weigh In

华尔街分析师也加入进来

A number of equities analysts have weighed in on STAA shares. BTIG Research lifted their price objective on STAAR Surgical from $98.00 to $103.00 in a research note on Thursday, August 11th. Benchmark upped their price objective on shares of STAAR Surgical from $97.00 to $117.00 and gave the stock a "buy" rating in a research report on Thursday, August 11th. Canaccord Genuity Group increased their price target on STAAR Surgical from $89.00 to $97.00 in a research report on Thursday, August 11th. Jefferies Financial Group dropped their price target on shares of STAAR Surgical from $165.00 to $125.00 in a research note on Thursday, August 11th. Finally, Needham & Company LLC upped their price target on shares of STAAR Surgical from $87.00 to $110.00 and gave the stock a "buy" rating in a research report on Thursday, August 11th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, STAAR Surgical presently has an average rating of "Moderate Buy" and an average target price of $106.83.

许多股票分析师已对STAA的股票进行了加码。BTIG Research在8月11日星期四的一份研究报告中将STAAR Surgical的目标价从98美元上调至103.00美元。在8月11日周四的一份研究报告中,Benchmark将STAAR Surgical的股票目标价从97美元上调至117.00美元,并给予该股“买入”评级。在8月11日星期四的一份研究报告中,Canaccel Genuity Group将STAAR Surgical的目标价从89.00美元上调至97.00美元。杰富瑞金融集团在8月11日星期四的一份研究报告中将STAAR Surgical的股票目标价从165.00美元下调至125.00美元。最后,Needham&Company LLC在8月11日(星期四)的一份研究报告中将STAAR Surgical的股票目标价从87美元上调至110.00美元,并给予该股“买入”评级。一位研究分析师对该股的评级为持有,五位分析师对该公司的评级为买入。根据MarketBeat.com的数据,星空外科目前的平均评级为“中等买入”,平均目标价为106.83美元。

Insider Transactions at STAAR Surgical

STAAR Surgical的内幕交易

In other STAAR Surgical news, CTO Keith Holliday sold 16,582 shares of the firm's stock in a transaction on Monday, August 15th. The stock was sold at an average price of $106.29, for a total transaction of $1,762,500.78. Following the completion of the sale, the chief technology officer now owns 19,437 shares of the company's stock, valued at $2,065,958.73. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 2.60% of the company's stock.

在STAAR Surgical的其他新闻中,CTO Keith Holliday在8月15日星期一的一次交易中出售了16,582股该公司的股票。该股以106.29美元的平均价格出售,总成交金额为176250.78美元。出售完成后,这位首席技术官现在拥有该公司19,437股股票,价值2,065,958.73美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,可以通过这个超级链接获得。内部人士持有该公司2.60%的股份。

STAAR Surgical Company Profile

STAAR外科公司简介

(Get Rating)

(获取评级)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

STAAR Surgical Company与其子公司一起设计、开发、制造、营销和销售眼科植入性镜片,以及将镜片输送到眼睛内的配套输送系统。该公司提供治疗近视、远视、散光和老花眼等视觉障碍的Visian植入式Collamer透镜产品系列(ICL),以及治疗远视的远视ICL。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on STAAR Surgical (STAA)
  • 3 High Margin Chipmakers Bound to Recover
  • 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
  • REV Group Has A Deep Moat In The World Of EVs
  • Is G-III Apparel Group, Ltd. A Value Trap?
  • Bank Of America Sees Upside In These 2 European Alcohol Stocks
  • 免费获取StockNews.com关于STAAR Surgical(STAA)的研究报告
  • 3家高利润率芯片制造商势必复苏
  • 将受益于拜登关税假期的3只太阳能股
  • REV集团在电动汽车世界拥有深厚的护城河
  • G-III服装集团有限公司是价值陷阱吗?
  • 美国银行看好这两只欧洲酒类股票

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.

接受《STAAR外科日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对STAAR外科及相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发